The Ottawa Hospital Cancer Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Laurie, Scott A
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting
2
60
Canada
Durvalumab, Prednisone, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Cancer
04/30
04/31
TWT-101, NCT04521413: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
170
Canada, US, RoW
CFI-402411, 2411, 402411, Pembrolizumab, Keytruda, pembro
Treadwell Therapeutics, Inc, TIO Discovery Engine
Advanced Solid Malignancies
11/24
12/24
NCT03990454: Safety Study of SLC-391 in Subjects With Solid Tumors

Completed
1
35
Canada
SLC-391
SignalChem Lifesciences Corporation
Solid Tumor
06/23
06/23
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
Asmis, Tim
POISE, NCT04871412: The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III

Recruiting
3
20
Canada
Vitamin D3 Drops, Vitamin D, Coriolus Versicolor, Trident SAP 66:33 Lemon, Fish Oil, Probiotic Pro12, Probiotics, Provitalix Pure Whey Protein, Protein Powder, Theracurmin 2X, Curcumin, Green Tea Extract, EGCG, Nutrition Recommendations, Physical Activity Recommendations, Psychological Recommendations
Ottawa Hospital Research Institute, The Canadian College of Naturopathic Medicine, Lotte & John Hecht Memorial Foundation, The Centre for Health Innovation, University of Ottawa
Lung Cancer, Gastric Cancer, Esophageal Cancer
12/29
12/31
Melosky, Barbara Lynn
EA5163, NCT03793179: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active, not recruiting
3
600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
09/27
09/27
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active, not recruiting
2
4
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
Ng, Terry
REaCT-5G, NCT04781959: A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Active, not recruiting
4
233
Canada
Filgrastim, Neupogen, Pegfilgrastim, Neulasta
Ottawa Hospital Research Institute
Early-stage Breast Cancer
10/23
12/23
REaCT-HOLD BMA, NCT04549207: Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Active, not recruiting
4
240
Canada
Bone modifying agent, Zoledronate, Denosumab, Pamidronate
Ottawa Hospital Research Institute
Breast Cancer, Castration-resistant Prostate Cancer
06/25
06/26
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
TRICIA, NCT04874064: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

Recruiting
N/A
130
Canada
Liquid Biopsy
Jewish General Hospital, Exactis Innovation
Breast Cancer
06/22
06/23
THERABIOME-GBM, NCT05326334: THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation

Recruiting
N/A
20
Canada
Ottawa Hospital Research Institute
Glioblastoma, IDH-wildtype
07/25
09/29
Liu, Geoffrey
OCELOT, NCT04335292: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting
2
200
Canada
Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
Mark Vincent, AstraZeneca
Non-Small Cell Lung Cancer
06/26
06/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
NCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Recruiting
N/A
425
Canada
Breathprint analysis and patient-reported outcomes
University Health Network, Toronto, University of Amsterdam
NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer
05/24
05/24
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
McAleer, Lena
NCT03990454: Safety Study of SLC-391 in Subjects With Solid Tumors

Completed
1
35
Canada
SLC-391
SignalChem Lifesciences Corporation
Solid Tumor
06/23
06/23
Tremblay, Nathalie
TRICIA, NCT04874064: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

Recruiting
N/A
130
Canada
Liquid Biopsy
Jewish General Hospital, Exactis Innovation
Breast Cancer
06/22
06/23
NCT04564079: An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

Recruiting
N/A
100
Canada
Exactis Innovation
NSCLC
07/23
08/23
NCT02355171: Personalize My Treatment (PMT) Registry

Recruiting
N/A
10000
Canada
Exactis Innovation
Cancer
07/25
07/25

Download Options